ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
CD169
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivePeriodontal bone regeneration remains a major challenge in in the treatment of periodontitis. This study we aimed to investigate whether there are CD169⁺ macrophages in periodontal tissues and the functions of these cells in the progressive and resolving phases of periodontitis.
methodsImmunofluorescence staining was performed to localize CD169⁺ macrophages in human and murine periodontal tissues. Subsequently, CD169⁺ macrophages from mature bone marrow-derived macrophages (BMDMs) were isolated. To characterize their functional properties, we assessed the phagocytic capacity of CD169⁺ macrophages in vitro. Furthermore, CD169⁺ macrophages were co-cultured to evaluate their osteogenic-promoting effects by qPCR, alkaline phosphatase (ALP) staining, and alizarin red staining (ARS). For in vivo validation, ligature-induced periodontitis (LIP) mice were established and local bacterial inoculated to investigate phagocytic function of CD169⁺ macrophages. Anti-interferon-alpha/beta receptor (Anti-IFNAR1) was injected locally to inhibit the signaling of IFN Is. Bone repair was assessed using micro-computed tomography (micro-CT) and histological staining.
resultsCD169 was primarily expressed on macrophages in periodontal tissues. In vitro CD169⁺ macrophages were positively induced by IFN Is. CD169⁺ macrophages exhibited robust phagocytic activity in clearing Porphyromonas gingivalis (P. gingivalis). Moreover, CD169⁺ macrophages promoted the osteogenic differentiation of BMSCs through the secretion of interleukin 10 (IL10), as evidenced by upregulated expression of osteogenesis-related genes (including Alpl, Sp7, Ibsp and Bglap), enhanced activity of ALP, and increased formation of mineralized nodules. In vivo results further demonstrated that CD169⁺ macrophages exhibited a high phagocytic capacity against P. gingivalis compared. During the resolving phase of periodontitis, a decrease in the number of CD169⁺ macrophages resulting from Anti-IFNAR1 application not only impaired alveolar bone repair, but also reduced expression of IL10 and osteogenesis-related proteins, such as OSX(Sp7) and OCN(Bglap).
conclusionsCD169⁺ macrophages play a critical role in periodontitis by clearing of P. gingivalis during the progressive phase of periodontitis, and promoting bone repair via the secretion of IL10 during the resolving phase.
Indexed as
Identifiers
41843164What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.